✦ LIBER ✦

Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial

✍ Scribed by Alice Gottlieb; Alan Menter; Alan Mendelsohn; Yaung-Kaung Shen; Shu Li; Cynthia Guzzo; Scott Fretzin; Rod Kunynetz; Arthur Kavanaugh

Book ID: 117304280
Publisher: The Lancet
Year: 2009
Tongue: English
Weight: 175 KB
Volume: 373
Category: Article
ISSN: 0140-6736
DOI: 10.1016/s0140-6736(09)60140-9

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Efficacy and safety of ustekinumab, a hu

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)

✍ Craig L Leonardi; Alexa B Kimball; Kim A Papp; Newman Yeilding; Cynthia Guzzo; Y 📂 Article 📅 2008 🏛 The Lancet 🌐 English ⚖ 222 KB

Efficacy and safety of ustekinumab, a hu

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)

✍ Kim A Papp; Richard G Langley; Mark Lebwohl; Gerald G Krueger; Philippe Szapary; 📂 Article 📅 2008 🏛 The Lancet 🌐 English ⚖ 295 KB

Anti-interleukin-17A monoclonal antibody

Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial

✍ Baeten, Dominique; Baraliakos, Xenofon; Braun, Jürgen; Sieper, Joachim; Emery, P 📂 Article 📅 2013 🏛 The Lancet 🌐 English ⚖ 780 KB

Treatment of rheumatoid arthritis with h

Treatment of rheumatoid arthritis with humanized anti–interleukin-6 receptor antibody: A multicenter, double-blind, placebo-controlled trial

✍ Norihiro Nishimoto; Kazuyuki Yoshizaki; Nobuyuki Miyasaka; Kazuhiko Yamamoto; Sh 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 163 KB 👁 3 views

## Abstract ## Objective Interleukin‐6 (IL‐6) is a pleiotropic cytokine that regulates the immune response, inflammation, and hematopoiesis. Overproduction of IL‐6 plays pathologic roles in rheumatoid arthritis (RA), and the blockade of IL‐6 may be therapeutically effective for the disease. This s

Efficacy and safety of secukinumab, a fu

Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial

✍ McInnes, I. B.; Sieper, J.; Braun, J.; Emery, P.; van der Heijde, D.; Isaacs, J. 📂 Article 📅 2013 🏛 BMJ Publishing Group 🌐 English ⚖ 471 KB

Ustekinumab, an anti-IL-12/23 p40 monocl

Ustekinumab, an anti-IL-12/23 p40 monoclonal antibody, inhibits radiographic progression in patients with active psoriatic arthritis: results of an integrated analysis of radiographic data from the phase 3, multicentre, randomised, double-blind, placebo-controlled PSUMMIT-1 and PSUMMIT-2 trials

✍ Kavanaugh, Arthur (author);Ritchlin, Christopher (author);Rahman, Proton (author 📂 Article 📅 2014 🏛 BMJ Publishing Group 🌐 English ⚖ 984 KB